Table 1 Baseline characteristics of cohorts in all included studies
Studies | area | PLA2R/anti-PLA2R (+/-) | Testing location | Testing Method | Follow-up (month) | NOS scores |
|---|---|---|---|---|---|---|
Wang LJ 2016 | China | 40/16 | renal tissues | IFA | 12 | 8 |
Liu H 2016 | China | 56/11 | renal tissues | IFA | >12 | 8 |
Pourcine F 2017 | France | 69/8 | serum | ELISA | 168 | 8 |
Ramachandran R 2016 | India | 94/20 | serum | ELISA | 12 | 7 |
Beck LH 2011 | Canada | 25/10 | serum | WB | 24 | 8 |
Wang J 2017 | China | 78/13 | renal tissues | IFA | 15 | 7 |
Bech AP 2014 | Hollan | 34/14 | serum | ELISA | 60 | 8 |
Zhou GY 2017 | China | 40/16 | serum | ELISA | 6 | 7 |
Qin W 2011 | China | 49/11 | serum | ELISA | >12 | 5 |
Oh YJ 2013 | Korea | 69/31 | serum | WB | 30 | 8 |
Kim YG2015 | Korea | 41/52 | serum | ELISA | 24 | 7 |
Ruggenenti P 2015 | France | 81/20 | serum | ELISA | 12 | 6 |
Timmermans SA 2015 | Hollan | 65/8 | serum | IFA | 11.3 | 6 |
Hofstra JM 2012 | Europe | 82/28 | serum | IFA、ELISA | 54 | 6 |
Liang Y 2017 | China | 42/37* | serum | ELISA | 12 | 7 |
Huang J 2017 | China | 29/11 | serum | IFA | >12 | 7 |
Zhang D 2018 | China | 164/28 | serum | ELISA | >13.6 | 7 |
Li Q 2018 | China | 177/73 | serum | ELISA | >6 | 7 |